Results 251 to 260 of about 162,270 (298)

A Multiscale Quantitative Systems Pharmacology Model for the Development and Optimization of mRNA Vaccines. [PDF]

CPT Pharmacometrics Syst Pharmacol
Dasti L, Giampiccolo S, Pettinà E, Fiandaca G, Zangani N, Leonardelli L, Hedayioglu FL, Campanile E, Marchetti L.   +8 more
europepmc   +1 more source

Mpox and the Ethics of Outbreak Management: Lessons for Future Public Health Crises

Developing World Bioethics, EarlyView.
ABSTRACT Mpox, first identified in captive monkeys in 1958 and recognized in humans by 1970 in the Democratic Republic of Congo, was historically confined to sporadic zoonotic outbreaks in Central and West Africa. These outbreaks, often driven by rodent‐to‐human transmission in resource‐limited settings, reflect persistent systemic health disparities ...
Adetayo E. Obasa, Marietjie Botes, Anita Kleinsmidt, Ciara Staunton   +3 more
wiley   +1 more source

Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges. [PDF]

Animal Model Exp Med
Zheng L, Feng H.
europepmc   +1 more source

The mRNA component of LNP-mRNA vaccines triggers IFNAR-dependent immune activation which attenuates the adaptive immune response. [PDF]

Front Immunol
Bar-On L, Cohen H, Elia U, Cherry-Mimran L, Cohen O, Erez N.   +5 more
europepmc   +1 more source

Emerging Immunotherapies in Lung Cancer: The Latest Advances and the Future of mRNA Vaccines. [PDF]

Vaccines (Basel)
Ramos R, Vale N.
europepmc   +1 more source

Engineering Universal Cancer Immunity: Non-Tumor-Specific mRNA Vaccines Trigger Epitope Spreading in Cold Tumors. [PDF]

Vaccines (Basel)
Magoola M, Niazi SK.
europepmc   +1 more source

Exploring the potential of saponins as adjuvants in lipid-nanoparticle-based mRNA vaccines. [PDF]

Mol Ther Methods Clin Dev
Eygeris Y, Jozic A, Henderson MI, Nelson D, Sahay G.   +4 more
europepmc   +1 more source

Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines against SARS-CoV-2. [PDF]

iScience
Singh ON, Berry U, Joshi G, Asuru TR, Chandrasekar K, Narayanan S, Srivastava P, Tiwari M, Chattopadhyay S, Mehdi F, Panda BN, Nayak D, Mani S, Shrivastava T, Batra G, Ranjith-Kumar CT, Guchhait P, Surjit M.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

mRNA vaccines

Nature Biotechnology, 2021
The concept of developing mRNA as vaccine platform evolved over the last decades. mRNA uses host cells for antigen production, can induce B and T cell responses and does not rely on unwanted antigens that may interfere with booster doses like vector vaccines.
openaire   +3 more sources